Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Aims: Transient elastography is increasingly being used in patients with chronic liver disease. It has proven particularly useful to identify patients with advanced fibrosis or cirrhosis, while classification of no or little fibrosis appears to be difficult. In general, stiffness values <6 kPa are considered normal, whereas patients with higher levels are candidates for a disease-specific treatment or further diagnostic evaluation. Parameters influencing liver stiffness may include food intake that increases liver blood flow.
Methods: In a pilot study, transient elastography was performed in eight patients with chronic hepatitis C at fasting and serially for 180 min after intake of a standardized breakfast. Confirmatory, 56 patients and 19 controls underwent liver stiffness determination at fasting, directly after meal intake and 1 h after breakfast.
Results: Liver stiffness significantly increased immediately after food intake for up to 60 min (P=0.01) before normalizing after 180 min. An intraindividual analysis showed a significant increase in 22 out of 43 patients with an initial liver stiffness
Conclusion: Food intake increases liver stiffness in patients with hepatitis C virus infection and healthy controls. To standardize liver stiffness evaluation, we suggest measurement in the fasting condition.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1478-3231.2009.02100.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IGLV3-21-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia.
Haematologica
September 2025
Division of Medical Oncology, University Hospital Basel, Basel, Switzerland; Laboratory of Translational Immuno-Oncology, Department of Biomedicine, University and University Hospital Basel, Basel.
We previously used a disease-specific B cell receptor (BCR) point mutation (IGLV3-21R110) for selective targeting of a high-risk subset of chronic lymphocytic leukemia (CLL) with chimeric antigen receptor (CAR) T cells. Since CLL is a disease of the elderly and a significant fraction of patients is not able to physically tolerate CAR T cell treatment, we explored bispecific antibodies as an alternative for precision targeting of this tumor mutation. Heterodimeric IgG1-based antibodies consisting of a fragment crystallizable region (Fc) attached to both an anti-IGLV3-21R110 Fab and an anti-CD3 (UCHT1) single chain variable fragment (R110-bsAb) selectively killed cell lines engineered to express high levels of the neoepitope as well as primary CLL cells using healthy donor and CLL patient-derived T cells as effectors.
View Article and Find Full Text PDFImpact of SGLT2 inhibitors on the risk of age-related ocular diseases in patients with type 2 diabetes mellitus: A target trial emulation study.
Diabetes Obes Metab
September 2025
Department of Pharmacy, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan.
Aims: Chronic ocular diseases such as age-related macular degeneration (AMD) are leading causes of vision loss in older adults. While sodium-glucose co-transporter 2 inhibitors (SGLT2i) are widely prescribed in the management of type 2 diabetes mellitus (T2DM), their effects on ocular disease risk remain largely unknown.
Materials And Methods: This retrospective cohort study evaluated the association between SGLT2i use and the risk of AMD and other age-related ocular conditions in adults aged ≥60 with T2DM, using a target trial emulation framework based on the TriNetX global health research network (2013-2025).
[Biomarkers for an early detection of patients at risk of renal or cardiovascular disease].
Rev Med Liege
September 2025
Service de Chimie clinique, CHU Liège, Belgique.
Chronic kidney disease (CKD), heart failure (HF) and atherosclerotic cardiovascular disease (ASCVD) are pathologies that may remain silent for a long time and thus are largely underdiagnosed in clinical practice. The use of biomarkers may help detect people already suffering from these diseases at an early stage or at increased risk to develop them in a near future. The aim of this article is to discuss the place of the assays of albuminuria, natriuretic peptide (BNP/proBNP) and high-sensitivity troponin as well as lipoprotein(a) to help in the diagnosis and prognosis assessment of individuals at risk of presenting or developing a CKD, HF or ASCVD.
View Article and Find Full Text PDF[Plea for an early diagnosis of people at risk of developing symptomatic type 1 diabetes].
Rev Med Liege
September 2025
Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Liège, Belgique.
Type 1 diabetes (T1D) is an autoimmune chronic disease that leads to the destruction of pancreatic beta cells and thus requires lifelong insulin therapy. Constraints and adverse events associated to insulin therapy are well known as well as the risk of long-term complications linked to chronic hyperglycaemia. Symptomatic T1D is preceded by a preclinical asymptomatic period, which is characterized by the presence of at least two auto-antibodies against beta cell without disturbances of blood glucose control (stage 1) or, in addition to immunological biomarkers, by the presence of mild dysglycaemia reflecting a defect of early insulin secretion (stage 2).
View Article and Find Full Text PDF[One-year clinical results of the Multidisciplinary Consultation at the Emphysema Clinic of CHU Liege].
Rev Med Liege
September 2025
Service de Pneumologie, CHU Liège, Belgique.
Severe emphysema impairs lung function and quality of life in patients with Chronic Obstructive Pulmonary Disease (COPD). Despite optimized medical treatment and rehabilitation, some patients require lung volume reduction interventions (endoscopic or surgical). This study evaluates one-year outcomes of patients managed at the Emphysema Clinic of CHU Liège.
View Article and Find Full Text PDF